Enveda Biosciences adds $55M to Series B raise

BOULDER — Enveda Biosciences, a biotechnology company also known as Enveda Therapeutics Inc. that uses artificial intelligence to develop new medicines, recently added $55 million more to its $119 million Series B fundraising round completed in 2023.  

The latest investment, which included new investors such as Premji Invest, Lingotto Investment Fund, Microsoft Corp. (Nasdaq: MSFT) and The Nature Conservancy, come as the company is set to begin several clinical trials in late 2024 and early 2025.

“Enveda’s lead program for atopic dermatitis is a novel oral first-in-class anti-inflammatory agent that has demonstrated remarkable efficacy and high safety margins in preclinical studies,” the company said in a news release. “Close on its heels is another novel first-in-class anti-inflammatory that inhibits multiple cytokine signaling cascades in the gut to achieve robust efficacy in models of inflammatory bowel disease.”

SPONSORED CONTENT

Care and coverage together for your employees

At Kaiser Permanente, we offer a unique care model. Not only do we provide care and coverage together (i.e. health plans and health care), but we also pioneered value-based care.

Founded in 2019, Enveda has raised a total of about $230 million from investors.